Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afuresertib - Laekna Therapeutics

Drug Profile

Afuresertib - Laekna Therapeutics

Alternative Names: 2110183; Afuresertib hydrochloride; ASB-183; GSK-2110183; GSK2110183B; GSK2110183C; LAE 002

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; Laekna Therapeutics; Novartis Oncology; University Health Network
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II HER2 negative breast cancer; Prostate cancer; Solid tumours
  • Discontinued Cancer; Chronic lymphocytic leukaemia; Gastric cancer; Haematological malignancies; Histiocytosis; Multiple myeloma

Most Recent Events

  • 23 May 2024 US FDA approves IND application for phase-III trial for Afuresertib in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater)
  • 11 Dec 2023 Efficacy and safety data from a phase I trial in HER2-negative-breast cancer released by Laekna Therapeutics
  • 05 Dec 2023 Efficacy and adverse events data from a phase I trial in HER2-negative-breast-cancer presented at the 46th Annual San Antonio Breast Cancer Symposium, 2023 (SABCS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top